BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24010908)

  • 1. PET/computed tomography and lymphoma.
    Allen-Auerbach M; de Vos S; Czernin J
    Radiol Clin North Am; 2013 Sep; 51(5):833-44. PubMed ID: 24010908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
    Allen-Auerbach M; de Vos S; Czernin J
    Radiol Clin North Am; 2008 Mar; 46(2):199-211, vii. PubMed ID: 18619376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of FDG-PET imaging in the management of lymphoma.
    Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
    Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes.
    Wray R; Solnes L; Mena E; Meoded A; Subramaniam RM
    PET Clin; 2015 Jul; 10(3):423-30. PubMed ID: 26099676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
    Kumar R; Xiu Y; Zhuang HM; Alavi A
    Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normal and abnormal patterns of 18F-fluorodeoxyglucose PET/CT in lymphoma.
    Bar-Shalom R
    Radiol Clin North Am; 2007 Jul; 45(4):677-88, vi-vii. PubMed ID: 17706532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET/CT imaging as a biomarker in lymphoma.
    Meignan M; Itti E; Gallamini A; Younes A
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):623-33. PubMed ID: 25573631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of positron emission tomography-computed tomography in gastrointestinal malignancies.
    Banks KP; Song WS
    Radiol Clin North Am; 2013 Sep; 51(5):799-831. PubMed ID: 24010907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of positron emission tomography/computed tomography (PET/CT) in head and neck cancer.
    Escott EJ
    Radiol Clin North Am; 2013 Sep; 51(5):881-93. PubMed ID: 24010911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
    Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [F-18 fluorodeoxyglucose positron emission tomography in malignant lymphoma].
    Mikosch P
    Wien Med Wochenschr; 2002; 152(11-12):269-75. PubMed ID: 12138654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
    Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
    Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET/CT: appropriate application in lymphoma.
    Wang X
    Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
    Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
    Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
    Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
    Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
    Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of
    Kaste SC; Snyder SE; Metzger ML; Sandlund JT; Howard SC; Krasin M; Shulkin BL
    J Nucl Med; 2017 Mar; 58(3):419-424. PubMed ID: 27609791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of PET and PET/CT in managing the care of lymphoma patients.
    Evans WC; Gilmore D; English J
    J Nucl Med Technol; 2011 Sep; 39(3):190-4. PubMed ID: 21795369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.